DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification that on 10 December 2020 Mr Bob Sutcliffe, the Chairman, purchased 13,333 Ordinary Shares in the Company at a price of 7.5p per share.
Following the transaction specified above Mr Sutcliffe has a beneficial holding of 545,382 Ordinary Shares representing 1.30% of the issued share capital of the Company.
| 1
|
Details of the person discharging managerial responsibilities / person closely associated | ||||
| a)
|
Name
|
Robert Sutcliffe
|
|||
| 2 | Reason for the notification | ||||
| a)
|
Position/status
|
Chairman | |||
| b)
|
Initial notification /Amendment
|
Initial | |||
| 3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
| a)
|
Name
|
DXS INTERNATIONAL PLC | |||
| b)
|
LEI
|
2138001R1KEUWTXEVJ44 | |||
| 4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a)
|
Description of the financial instrument, type of instrument | Ordinary Shares of 0.33p each | |||
| Identification code | ISIN GB00B2Q6HZ92 | ||||
| b)
|
Nature of the transaction
|
Purchase | |||
| c)
|
Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 7.5p | 13,333 | ||||
| d)
|
Aggregated information | ||||
| – Aggregated volume | |||||
| – Price | |||||
| e)
|
Date of the transaction
|
10 December 2020 | |||
| f)
|
Place of the transaction
|
AQSE | |||
The Directors of DXS International plc accept responsibility for this announcement
Enquiries:
| David Immelman (Chief Executive) DXS International plc |
01252 719800 david@dxs-systems.com |
| Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS |
|
| www.dxs-systems.co.uk |
| Corporate Advisor
|
|
| David Papworth City & Merchant |
0207 101 7676
|
| Corporate Broker
|
|
| Hybridan LLP Claire Louise Noyce
|
020 3764 2341
|
Note to Editors:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.
OTTAWA, ON, June 17, 2024 /CNW/ - Today, the Honourable François-Philippe Champagne, Minister of Innovation,…
Newly Embedded Prior Authorizations in the Parachute Platform Reduce Costs and Streamlines Administration for Health Plans,…
- Company invited to speak during three symposia on the impact of quality improvement, the…
REDDING, Calif., June 17, 2024 /PRNewswire/ -- According to a new market research report, 'Dental 3D…
TEL AVIV, Israel, June 17, 2024 /PRNewswire/ -- Briya, a leading medical data retrieval network,…
Potential partners are invited to explore collaboration opportunities with VUNO Med®-DeepBrain®, a highly accurate AI…